2. Academic Validation
  3. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate

The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate

  • Bioorg Med Chem Lett. 2001 Apr 9;11(7):895-8. doi: 10.1016/s0960-894x(01)00078-6.
S J Macdonald 1,  M D Dowle,  L A Harrison,  P Shah,  M R Johnson,  G G Inglis,  G D Clarke,  R A Smith,  D Humphreys,  C R Molloy,  A Amour,  M Dixon,  G Murkitt,  R E Godward,  T Padfield,  T Skarzynski,  O M Singh,  K A Kumar,  G Fleetwood,  S T Hodgson,  G W Hardy,  H Finch
Affiliations

Affiliation

  • 1 Medicinal Chemistry 2, GlaxoWellcome Medicines Research Centre, Stevenage, UK. sjfm5947@glaxowellcome.co.uk
PMID: 11294386 DOI: 10.1016/s0960-894x(01)00078-6
Abstract

The discovery of a potent intracellular inhibitor of human neutrophil Elastase which is orally active and has a long duration of action is described. The pharmacodynamic and pharmacokinetic properties of a trans-lactam development candidate, GW311616A, are described.

Figures
Products